Samphire Neurosciences

Executive Summary

Samphire Neurosciences is a UK-based women's health technology company founded in 2021 that develops non-invasive, drug-free neurotechnology devices and software to manage menstrual cycle-related symptoms such as pain, low mood, and brain fog. The company's approach leverages neuroplasticity to balance brain activity across the hormonal cycle, offering a novel alternative to pharmacological interventions. Operating in the neuroscience and rare disease categories, Samphire targets a large unmet need in women's health, where current treatments are often limited or have significant side effects. As a private company with no disclosed funding or valuation, it is still in early stages, but its focus on digital therapeutics and wearable neurotechnology positions it in a rapidly growing market. The success of the company will depend on clinical validation, regulatory approvals, and commercial adoption.

Upcoming Catalysts (preview)

• Q1 2027Clinical study results demonstrating efficacy of neurotechnology device40% success
• Q2 2027Regulatory clearance (e.g., CE mark or UKCA) for device50% success
• Q3 2026Series A funding round or strategic partnership60% success